The long-term safety and efficacy of 0.01% halobetasol propionate and 0.045% tazarotene (HP/TAZ) lotion in patients with psoriasis previously treated with topicals is evaluated.
Loading and maintenance doses of biologic agents for treatment of psoriasis compared with other inflammatory diseases is assessed.
The efficacy of deucravacitinib in patients with plaque psoriasis who did not respond to treatment with apremilast is evaluated.
Health-related quality of life in patients with psoriasis who received either bimekizumab (BKZ) or secukinumab (SEC) is compared.
Real-world treatment use of conventional and biologic agents in adult and pediatric patients with psoriasis are compared.
Is there an association between sleep quantity and cardiovascular disease in patients with psoriasis?
